B6-hOX40L (hTNFSF4) Mouse
Product Name
B6-hOX40L (hTNFSF4) Mouse
Product ID
C001719
Strain Name
C57BL/6NCya-Tnfsf4tm1(hTNFSF4)/Cya
Backgroud
C57BL/6NCya
When using this mouse strain in a publication, please cite “B6-hOX40L (hTNFSF4) Mouse (Catalog C001719) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
GP34, CD252, OX4OL, TXGP1, CD134L, OX-40L, TNLG2B
NCBI ID
Chromosome
Chr 1
MGI ID
Datasheet
Strain Description
The TNFSF4 gene (tumor necrosis factor superfamily member 4, also known as OX40L) encodes the OX40 ligand protein, a type II transmembrane protein mainly expressed on antigen-presenting cells (APCs, such as dendritic cells, B cells, and macrophages), as well as endothelial cells and smooth muscle cells [1]. This protein binds to the receptor OX40 (TNFRSF4) on the surface of T cells, providing crucial co-stimulatory signals that enhance T-cell proliferation, survival, and cytokine secretion, thereby playing a central role in adaptive immunity and inflammatory responses [2]. Dysregulated expression of TNFSF4 is associated with various autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and its gene polymorphisms have been proven to be related to disease susceptibility [3]. Altering the OX40-OX40L interaction can either enhance the immune response to fight cancer or suppress it to treat autoimmune diseases [4]. Blocking the OX40-OX40L binding may alleviate autoimmune diseases by reducing the levels of pro-inflammatory cytokines and enhancing the function of regulatory T cells. Due to its crucial role in immune regulation, OX40L is regarded as an important target for treating autoimmune diseases and cancer immunotherapy, and current drug development focuses on monoclonal antibodies and OX40L inhibitors.
B6-hOX40L (hTNFSF4) mice are a humanized model constructed by using gene editing technology to replace the endogenous extracellular domain of the mouse Tnfsf4 gene with the extracellular domain of the human TNFSF4 gene. This model can be used for research on autoimmune diseases (such as systemic lupus erythematosus and rheumatoid arthritis), cancer immunology, and TNFSF4-targeted drug development.
Reference
Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57-78.
Ishii N, Takahashi T, Soroosh P, Sugamura K. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol. 2010;105:63-98.
Cunninghame Graham DS, Graham RR, Manku H, Wong AK, Whittaker JC, Gaffney PM, Moser KL, Rioux JD, Altshuler D, Behrens TW, Vyse TJ. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet. 2008 Jan;40(1):83-9.
Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R. OX40/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024 Sep;43(3):1001-1013.
Strain Strategy
The mouse Tnfsf4 endogenous extracellular domain will be replaced with the human TNFSF4 extracellular domain.
Figure 1. Gene editing strategy of B6-hOX40L (hTNFSF4) mice.
Application Area
Screening, development, and preclinical efficacy evaluation of TNFSF4-targeted drugs;
Research on the pathological mechanisms and treatment methods of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA);
Research on cancer immunology.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.